Annals of Oncology 7:151-156, 1996
© 1996 European Society for Medical Oncology
research-article |
High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
1Department of Internal Medicine, Section of Oncology Hematology
2Department of Preventive and Societal Medicine, University of Nebraska Medical Center Omaha, NE, U.S.A.
Philip J. Bierman, M.D. University of Nebraska Medical Center 600 S. 42nd St. Omaha, NE 68198–3330, U.S.A.
Background: The best results of conventional-dose salvage chemotherapy for Hodgkin's disease have been reported after first relapse. We evaluated the results of high-dose chemotherapy and autologous hematopoietic rescue for Hodgkin's disease patients who had relapsed from an initial chemotherapy-induced complete remission.
Patients and methods: Eighty-five patients received high-dose cyclophosphamide, carmustine, and etoposide (CBV) followed by autologous bone marrow or peripheral blood stem cell transplantation.
Results: Actuarial survival at five years was 51%, and failure-free survival was 40%. Failure-free survival at five years was 90% for patients who received no conventional-dose salvage chemotherapy prior to CBV. Failure-free survival of patients treated initially with a four-drug regimen was not significantly different than patients treated with seven/eight-drug regimens.
Conclusion: These results appear to be better than those reported for conventional-dose salvage chemotherapy. High-dose therapy followed by autologous bone marrow or peripheral blood stem cell transplantation should be considered for any patient with relapsed Hodgkin's disease, regardless of the length of initial remission, or type of initial chemotherapy. Certain patients, especially those with minimal disease, may benefit by proceeding directly to transplantation after relapse, without first receiving conventional-dose salvage chemotherapy.
bone marrow transplantation, drug therapy, hematopoietic stem cell transplantation, Hodgkin's disease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Sureda, M. Constans, A. Iriondo, R. Arranz, M. D. Caballero, M. J. Vidal, J. Petit, A. Lopez, J. J. Lahuerta, E. Carreras, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse Ann. Onc., April 1, 2005; 16(4): 625 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Czyz, R. Dziadziuszko, W. Knopinska-Postuszuy, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, A. Avigdor, A. Nagler, et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients Ann. Onc., August 1, 2004; 15(8): 1222 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-E. Filmont, J. Czernin, C. Yap, D. H. S. Silverman, A. Quon, M. E. Phelps, and C. Emmanouilides Value of F-18 Fluorodeoxyglucose Positron Emission Tomography for Predicting the Clinical Outcome of Patients With Aggressive Lymphoma Prior to and After Autologous Stem-Cell Transplantation Chest, August 1, 2003; 124(2): 608 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Hematology, January 1, 2003; 2003(1): 225 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Bierman, J. C. Lynch, R. G. Bociek, V. L. Whalen, A. Kessinger, J. M. Vose, and J. O. Armitage The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation Ann. Onc., September 1, 2002; 13(9): 1370 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mink and J. O. Armitage High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma Oncologist, June 1, 2001; 6(3): 247 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sureda, R. Arranz, A. Iriondo, E. Carreras, J.J. Lahuerta, J. Garcia-Conde, I. Jarque, M.D. Caballero, C. Ferra, A. Lopez, et al. Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group J. Clin. Oncol., March 1, 2001; 19(5): 1395 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Santoro, H. Bredenfeld, L. Devizzi, H. Tesch, V. Bonfante, S. Viviani, F. Fiedler, H. S. Parra, C. Benoehr, M. Pacini, et al. Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study J. Clin. Oncol., July 1, 2000; 18(13): 2615 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Bogart, C. Ungureanu, S. Ryu, C. T. Chung, and K. W. Zamkoff Hematologic Toxic Reaction to Radiation Therapy Adjuvant to Autologous Peripheral Blood Stem Cell Transplantation for Recurrent or Refractory Hodgkin Disease Radiology, February 1, 2000; 214(2): 421 - 425. [Abstract] [Full Text]
|
|
|
|
|
|
K. S. Baker, B. G. Gordon, T. G. Gross, M. A. Abromowitch, E. R. Lyden, J. C. Lynch, J. M. Vose, J. O. Armitage, P. F. Coccia, and P. J. Bierman Autologous Hematopoietic Stem-Cell Transplantation for Relapsed or Refractory Hodgkin's Disease in Children and Adolescents J. Clin. Oncol., March 1, 1999; 17(3): 825 - 825. [Abstract] [Full Text] [PDF]
|
|